Invitrogen ADDS Genetix clonepix<SUP>FL</SUP> technology to process development services
24 Jul 2006
Invitrogen Corporation (Nasdaq:IVGN) and Genetix Group plc (LSE: GTX) announced today an agreement which allows Invitrogen to utilize the Genetix ClonePixFL technology in process development services offered through PD-Direct™. The Genetix ClonePixFL is an instrument that automatically images, selects and picks mammalian cell colonies based upon a number of parameters such as size, roundness and proximity to neighbors or far more specific information such as quantitative protein secretion or specific protein production.
“The Genetix ClonePix technology greatly enhances our ability to rapidly screen clones for the highest producers,” said Dr. Steve Feldman, PD-Direct™ Senior Scientist. “Genetix has developed an excellent tool and we are excited to make this technology available to our process development clients.”
“The pairing of Invitrogen’s cell line expertise with the high-throughput capability enabled by the Genetix ClonePixFL technology will lead to a step change in the way that cell biology is approached and the efficiency of cell line generation and engineering” said Genetix CSO Julian F. Burke PhD.
Invitrogen also announced that it will develop applications which integrate the ClonePixFL together with the Revolution™ technology to further enhance the optimization of parental cell lines and production clones.